Ann Dermatol.  2016 Dec;28(6):796-797. 10.5021/ad.2016.28.6.796.

Superficial Basal Cell Carcinoma Treated with Two Cycles of Ingenol Mebutate Gel 0.015%

• Jung YS
• Lee JH
• Bae JM
• Kim GM

• KMID: 2368144
• DOI: http://doi.org/10.5021/ad.2016.28.6.796

Abstract

No abstract available.

MeSH Terms

Carcinoma, Basal Cell*

Figure

• 

  Fig. 1 Clinical photographs. (A) Initial lesion, (B) day 2 (1 day after the first application), (C) day 3 (1 day after the second application), (D) day 4 (1 day after the third application), (E) day 5 (1 day after the fourth application), (F) ten weeks after the treatment.

• 

  Fig. 2 Histologic findings. (A) Initial lesion, (B) 10 weeks after the first treatment, (C) 10 weeks after the second treatment (H&E, ×40).

Reference

1. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006; 155:401–407.

2. Chen CC, Chen CL. Clinical and histopathologic findings of superficial basal cell carcinoma: a comparison with other basal cell carcinoma subtypes. J Chin Med Assoc. 2006; 69:364–371.

3. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010; 51:99–105.

4. Cantisani C, Paolino G, Cantoresi F, Faina V, Richetta AG, Calvieri S. Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05%. Dermatol Ther. 2014; 27:352–354.